Publication marks the first time in nearly two decades that The New England Journal of Medicine has

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, to

DexCom's strong margins, G7 15-day rollout and promising pipeline support its growth outlook, but fa

BTIG analyst Ryan Zimmerman maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target

HWG Holdings LP acquired a new stake in shares of DexCom, Inc. (NASDAQ: DXCM) in the undefined quart

Barclays analyst Christopher Pasquale initiates coverage on DexCom (NASDAQ:DXCM) with a Overweigh

[url="]DEXCOM[/url], INC. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today t

SAN DIEGO--(BUSINESS WIRE)--DEXCOM, INC. (NASDAQ: DXCM), the global leader in glucose biosensing, an

The Nasdaq 100 trades at records Monday, yet 55 of its 101 stocks sit below their 50-day average. QQ

Dexcom sees room to expand CGM adoption as low awareness, reimbursement hurdles and rising GLP-1 use

RBC Capital analyst Kendall Au maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the pr

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investi

Market Overview Stocks began their breakout to new all-time highs again, but it remains a highly

New global State of Type 2 Report uncovers three interconnected challenges in Type 2 diabetes care:

[url="]DexCom, Inc.[/url] (NASDAQ: DXCM), the global leader in glucose biosensing, today released it

MILAN--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today

DexCom, Inc. (NASDAQ: DXCM - Get Free Report) has been assigned a consensus rating of "Moderate Buy"

Oura Inc. NASDAQ: OURA launched its roadshow on Sept. 21, 2026, targeting a Nasdaq debut under the t

Truist Securities analyst Richard Newitter maintains DexCom (NASDAQ:DXCM) with a Buy and raises t

SAN DIEGO--(BUSINESS WIRE)--Dexcom Promotes Jereme Sylvain to Chief Operating Officer.

DXCM's strong growth, G7 15 Day adoption and CONNECT trial could expand its CGM market opportunity d

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, tod

DexCom, Inc. (DXCM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or ob

Technical indicators have turned bullish for the three stocks.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present

American Capital Management Inc. bought a new stake in DexCom, Inc. (NASDAQ: DXCM) in the undefined

The FDA authorized Abbott's Libre Duo 10 Day, the first wearable tracking both glucose and keton

ABT edges DXCM on price-target upside and valuation, while both pursue CGM growth through innovation

Argus Research analyst Steve Silver maintains DexCom (NASDAQ:DXCM) with a Buy and raises the pric

Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:DXCM) with a Buy and raises t

Citigroup analyst Joanne Wuensch maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price t

RBC Capital analyst Kendall Au maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the pr

Mizuho analyst Anthony Petrone maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the pr

Amazon surges 15% on an AWS blowout while Apple sheds nearly $475 billion in value. Yields sit at cy

JP Morgan analyst Robbie Marcus maintains DexCom (NASDAQ:DXCM) with a Neutral and raises the pric

Piper Sandler analyst Matt O'Brien reiterates DexCom (NASDAQ:DXCM) with a Overweight and rais

Wells Fargo analyst Larry Biegelsen maintains DexCom (NASDAQ:DXCM) with a Overweight and raises t

U.S. stocks mixed, Nasdaq up 50 pts. AXT Inc (NASDAQ: AXTI) rose 25.3% on strong Q2 results. Other g

Stifel analyst Jonathan Block maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price targ

Benchmark analyst Bruce D. Jackson maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price

Truist Securities analyst Richard Newitter maintains DexCom (NASDAQ:DXCM) with a Buy and raises t

BTIG analyst Marie Thibault maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target

DexCom (NASDAQ:DXCM) raises FY2026 sales outlook from $5.160 billion-$5.250 billion to $5.180 billio

DexCom (NASDAQ:DXCM) reported quarterly earnings of $0.70 per share which beat the analyst consensus

The FDA launched the TEMPO pilot to evaluate a new regulatory approach for certain digital health te

Truist Securities analyst Richard Newitter maintains DexCom (NASDAQ:DXCM) with a Buy and raises t

Mizuho analyst Anthony Petrone maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the pr

Dexcom G7 15 Day is the longest‑lasting and most accurate1-4 CGM system authorized by Health Canada,